Automate Your Wheel Strategy on ZYME
With Tiblio's Option Bot, you can configure your own wheel strategy including ZYME - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Zymeworks Announces Participation in Upcoming Investor Conferences
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
VANCOUVER, British Columbia, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will participate in the following upcoming investor conferences:
Read More
Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
VANCOUVER, British Columbia, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the appointment of Oleg Nodelman to its board of directors, effective February 17, 2025. Mr. Nodelman is the Founder and Managing Director of EcoR1 Capital, LLC, a biotech-focused investment advisory firm, which invests in companies at all stages of research and development.
Read More
Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
VANCOUVER, British Columbia, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will report its fourth quarter and full year 2024 financial results after market close on March 5, 2025. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on March 5, 2025 at 4:30 pm Eastern Time (ET).
Read More
About Zymeworks Inc. (ZYME)
- IPO Date 2017-04-28
- Website https://www.zymeworks.com
- Industry Biotechnology
- CEO Kenneth H. Galbraith
- Employees 299